A second cervical cancer vaccine may soon be available.
Drug-maker Glaxo-Smith-Kline is asking the food and drug administration to approve its cervical cancer vaccine called "Cervarix." The company just submitted final data on a phase iii clinical study involving more than 18,000 teen girls and women.
Like Merck's Gardasil already on the market, Cervarix works by protecting against the human papillomavirus, which is a cause of cervical cancer.
Cervarix is currently used in more than 90 countries. It could be approved by the FDA within about 6 months.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.